Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,084 recruiting studies in this area right now.
By phase
- Not applicable2,111
- Phase 21,115
- Phase 1823
- Phase 1/Phase 2481
- Phase 3348
- Phase 4127
- Phase 2/Phase 379
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia122
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema50
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center64
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California407
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida110
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,084 total
- NCT07021677RecruitingPhase 2
Daratumumab for leftover leukemia cells after T-ALL treatment
This trial tests if adding the drug daratumumab can clear remaining cancer cells in people with T-cell acute lymphoblastic leukemia (T-ALL) who still have a small amount of leukemia after initial chemotherapy. It aims to reduce the risk of the cancer coming back.
Navi Mumbai, MaharashtraAges 18–65 - NCT07022223RecruitingPhase 2
Orelabrutinib plus rituximab for first treatment of marginal zone lymphoma
This trial tests a combination of two targeted drugs, orelabrutinib and rituximab, as the first systemic treatment for marginal zone lymphoma. If you have not yet had chemotherapy for your lymphoma and meet certain health criteria, you may be able to join.
Hangzhou, ZhejiangAges 18 years+ - NCT07022834RecruitingPhase 2
New drug combo for high-risk LCH in children
This trial tests a combination of targeted therapy (dabrafenib or trametinib) with chemotherapy (clofarabine) for children with Langerhans cell histiocytosis (LCH) that is high-risk, has come back, or is not responding to other treatments. The goal is to see if this combination can help control the disease.
Chengdu, SichuanAges birth–18 years - NCT07022964RecruitingPhase 1/Phase 2
CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
BeijingAges 14–70 - NCT07023588RecruitingPhase 2
Optimizing AML treatment based on early response
This trial tests if adjusting chemotherapy based on early signs of leukemia can improve outcomes for people newly diagnosed with acute myeloid leukemia (AML). It might be a good fit if you are starting treatment and have a certain level of leukemia cells in your blood after a few days of therapy.
Changchun, JilinAges 18 years+ - NCT07023666RecruitingPhase 2
Early heart screening and treatment for sickle cell disease
This trial tests early screening and treatment to prevent heart problems in people with sickle cell disease. It focuses on those with high iron levels or heart symptoms, using regular heart imaging to monitor and treat complications early.
Fairfax, VirginiaAges 18 years+ - NCT07025005RecruitingPhase 4
Fenofibrate to prevent nerve damage from multiple myeloma treatment
This trial tests if adding fenofibrate to standard treatment (VRd) can prevent nerve damage (peripheral neuropathy) caused by bortezomib in patients with newly diagnosed multiple myeloma. If you are starting VRd therapy, this study may help reduce pain or numbness from the chemotherapy.
Damanhur, El- BehiraAges 18 years+ - NCT07028086RecruitingPhase 2
VAM for secondary or extramedullary AML
This trial tests a combination of three drugs (called VAM) in people whose acute myeloid leukemia (AML) is either secondary (came from another blood disorder), therapy-related (caused by previous cancer treatment), or has spread outside the bone marrow (extramedullary disease). It is for patients who have not yet received any treatment for their AML.
ShanghaiAges 18–65 - NCT07028970Recruiting
Long-term follow-up study for equecabtagene autoleucel recipients
This registry study will follow people who have received the CAR T-cell therapy equecabtagene autoleucel to monitor their long-term health and outcomes. It is open to those who completed or withdrew from an earlier study of this treatment.
BeijingAges Any age - NCT07029217RecruitingPhase 3
Lower radiation dose study for B-cell lymphomas
This study tests if a reduced dose of radiation therapy works well for certain types of B-cell lymphomas, specifically follicular lymphoma and marginal zone lymphoma. It aims to minimize side effects while still controlling the disease.
Basking Ridge, New JerseyAges 18 years+ - NCT07029503RecruitingPhase 2
Heart failure and kidney function study
This trial tests a new treatment for people with heart failure and severely reduced kidney function. It aims to see if the treatment can help protect both the heart and kidneys.
StockholmAges 18 years+ - NCT07030400Recruiting
Quality of life study for adults with CLL or SLL
This study looks at how health-related quality of life changes in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when starting a new treatment. The goal is to better understand what affects well-being during therapy.
Tampa, FloridaAges 18 years+ - NCT07032103Recruiting
Lymphoma study tracking patient outcomes over time
This study follows people with Hodgkin or non-Hodgkin lymphoma who need strong treatment to try to cure their cancer. The goal is to learn more about how the disease and its treatment affect patients over time.
SeoulAges Any age - NCT07032129RecruitingPhase 1/Phase 2
Targeted cell therapy for multiple myeloma that returned or didn't respond
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
Beijing, Beijing MunicipalityAges 21–90 - NCT07032714RecruitingPhase 1
Mezigdomide and talquetamab for relapsed multiple myeloma
This trial tests a combination of two drugs, mezigdomide (a pill) and talquetamab (an injection), for people with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to see if this combination can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT07035938Recruiting
T-Cell Health in Blood Cancer Patients Study
This study looks at how T-cells (a type of immune cell) work in people with certain blood cancers (B-cell lymphoma or multiple myeloma) compared to healthy volunteers. The goal is to learn more about the immune system in these cancers, which may help improve future treatments.
Xiamen, FujianAges 18 years+ - NCT07036133RecruitingPhase 1
Study of Pralatrexate in patients with advanced cancer and liver problems
This trial tests a drug called pralatrexate in people with advanced solid tumors or blood cancers, including those with different levels of liver function. The goal is to understand how the drug works in the body and how safe it is for patients with various degrees of liver impairment.
Cerritos, CaliforniaAges 18 years+ - NCT07036250RecruitingPhase 1/Phase 2
Study of U32 for acute myeloid leukemia
This trial tests a new treatment called U32 for people with acute myeloid leukemia (AML) that has come back or not responded to prior therapy. It aims to see if targeting certain proteins on leukemia cells can help control the disease.
SuzhouAges 2–65 - NCT07042438RecruitingPhase 2
Fecal transplant to improve CAR T therapy for lymphoma
This study tests whether a fecal transplant (transferring healthy gut bacteria) can improve outcomes for people with certain lymphomas who have taken strong antibiotics and are about to get CAR T-cell therapy (Yescarta). The goal is to see if rebuilding gut bacteria helps the treatment work better.
Duarte, CaliforniaAges 18 years+ - NCT07043894RecruitingPhase 2
Romiplostim for low platelets from chemo in kids
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
BeijingAges 6–24 - NCT07043946RecruitingPhase 1/Phase 2
Budoprutug for immune thrombocytopenia
This trial tests a new drug called budoprutug for people with immune thrombocytopenia (ITP), a condition where your immune system attacks your own platelets, causing low counts. The study aims to see if the drug can safely raise platelet levels and reduce bleeding risk.
PlovdivAges 18 years+ - NCT07044427Recruiting
Fall prevention exercise for multiple myeloma patients
This trial tests if a home exercise program can help prevent falls in people with multiple myeloma. It is for patients who are currently receiving or have recently received cancer therapy and want to exercise at least three times a week.
Heidelberg, Baden WürtembergAges 18 years+ - NCT07044544RecruitingPhase 1
New drug combo in stem cell transplant for myeloid cancers
This trial tests adding two new drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant for people with certain types of leukemia or myelodysplastic syndrome. The goal is to see if this combination can improve outcomes.
Birmingham, AlabamaAges 18–75 - NCT07046078RecruitingPhase 2
Chemo, radiation, and donor transplant for older adults with high-risk AML
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Seattle, WashingtonAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,084 recruiting hematology studies from the U.S. registry right now, out of 7,742 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.